CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 255 enrolled
Drug / intervention
Adjuvanted influenza H1N1split virion vaccinebiological
Likely dose
Adjuvanted influenza H1N1split virion vaccine 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01003288
NCT01003288N/ACompleted
CompareCT.gov

Safety and Immunogenicity Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen

University of Bergen·interventional·Posted Oct 28, 2009·Updated Nov 18, 2019

In Brief

A clinical study evaluating Adjuvanted influenza H1N1split virion vaccine for Healthy. Completed, enrolled 255 participants across 1 site.

Detailed Summary

Haukeland University Hospital has approximately 8000 employees many of whom will be in the front line to receive the pandemic A/H1N1 vaccine. We propose to conduct a safety and immunogenicity study in these subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesNorway
CollaboratorsHaukeland University Hospital

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 28, 2009
Enrollment StartOct 1, 2009
Primary CompletionJan 1, 2010
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.7 years ago

Interventions

Adjuvanted influenza H1N1split virion vaccinebiological

Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A) \* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)